Redx Pharma

Endeavor BioMedicines

This clinical-stage biotechnology company develops small-molecule inhibitors and therapies for patients with oncology and fibrotic lung diseases.

Pharmacyclics

This company develops small-molecule medicines for patients with cancer and immune-mediated diseases.

Origo Biopharma

This clinical-stage biotechnology company develops small molecule therapies targeting the transforming growth factor beta pathway to treat fibrosis and cancer in healthcare patients.

Calluna Pharma

This clinical-stage company develops monoclonal antibodies to treat inflammatory and fibrotic diseases for patients with conditions like idiopathic pulmonary fibrosis and chronic kidney disease.

Redona Therapeutics

This biotechnology company develops small molecule therapies targeting nucleic acid regulators to treat cancer and autoimmune diseases for healthcare providers and pharmaceutical partners.

Promedior

This biotechnology company develops drug therapies to treat rare fibrotic diseases for patients with conditions such as idiopathic pulmonary fibrosis and myelofibrosis.

Celea Therapeutics

The company develops deupirfenidone, an antifibrotic medicine for patients with idiopathic pulmonary fibrosis and other serious respiratory diseases.

Nuvectis Pharma

This biopharmaceutical company develops precision medicines and targeted small molecule therapeutics for patients with advanced cancers and other serious conditions.